Physician profile
David B Kessler
NPI 1255442232
$220,633.83
in general payments reported to CMS, 2019-2025
37 companies · $29K in 2025
The $29K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $26K · 2021: $31K · 2022: $31K · 2023: $27K · 2024: $29K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Food and Beverage: $7,752 · Travel and Lodging: $2,922 · Education: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,084.00 |
| Food and Beverage | $7,751.56 |
| Travel and Lodging | $2,921.67 |
| Education | $333.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $84,239.79 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $71,006.18 | 2019-2025 | Dupixent |
| Genzyme Corporation | $28,884.97 | 2019-2025 | |
| Incyte Corporation | $11,484.08 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $10,789.91 | 2019-2025 | |
| Janssen Biotech, INC. | $6,234.96 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $1,859.76 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $980.92 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $691.32 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $683.29 | 2019-2025 | Siliq, Targretin, Duobrii |
| Regeneron Pharmaceuticals, INC. | $478.65 | 2022-2025 | Dupixent |
| Genentech USA, INC. | $428.78 | 2019-2022 | |
| Biofrontera INC. | $379.70 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $342.52 | 2019-2025 | Taltz, Zepbound, Ebglyss |
| Sanofi-Aventis U.S. LLC | $267.98 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $264.58 | 2019-2022 | |
| Almirall LLC | $253.76 | 2019-2023 | Klisyri |
| Sun Pharmaceutical Industries INC. | $244.67 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $180.66 | 2024-2025 | Zoryve |
| Pfizer INC. | $152.65 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $132.03 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $115.31 | 2022-2024 | Sotyktu |
| Amgen INC. | $87.72 | 2019-2024 | Otezla |
| Epi Health, LLC | $60.71 | 2019-2021 | |
| Dermavant Sciences, INC. | $54.25 | 2022-2024 | Vtama |
| Merck Sharp & Dohme LLC | $47.24 | 2019 | |
| Genentech, INC. | $38.85 | 2023 | Erivedge |
| Medimetriks Pharmaceuticals, INC. | $37.51 | 2019 | |
| Dermira, INC. | $36.47 | 2019-2020 | |
| Strata Skin Sciences, INC. | $30.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.07 | 2022 | |
| Celgene Corporation | $23.98 | 2019 | |
| Glenmark Therapeutics INC. | $22.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $20.62 | 2023 | Nuzyra |
| Verrica Pharmaceuticals INC. | $19.60 | 2023 | Ycanth |
| Organogenesis INC. | $19.07 | 2023 | Puraply |
| Sandoz INC. | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.